Annaliesa Anderson | Vice President And Cso Bacterial Vaccines
Pfizer

Annaliesa Anderson, Vice President And Cso Bacterial Vaccines, Pfizer

Annaliesa Anderson PhD FAAM, has over 20 years of pharmaceutical research experience and is currently the Chief Scientific Officer for Bacterial Vaccines at Pfizer Inc. Her responsibilities include infectious disease vaccine R and D, surveillance and the assessment of the immunopathology of bacterial colonization and disease. Dr Andersons experience includes leadership roles for bacterial vaccine programs directed at the prevention of diseases due to Neisseria meningitidisStaphylococcus aureus and Clostridium difficile and Enterococcus sp. In this role, she has made substantial contributions to vaccine antigen discovery, preclinical proof of concept, clinical proof of concept and recently the licensure of the N. meningitidis serogroup B vaccine Trumenba®.

Appearances:



Day 2 - 10 Co-conferences @ 10:15

Experts in bacterial vaccines critiquing FireChats

Day 3 - 10 Co-conferences & Plenary @ 10:10

Are bacterial vaccines harder to develop?

  • What are the challenges in clinical efficacy trials?
  • Phase II Clostridium difficile vaccine
last published: 18/Jan/19 09:26 GMT

back to speakers

Sign Up for Event Updates

Get Involved At World Vaccine Congress Washington

 

To Sponsor Or Exhibit

Marc Rhys-Evans
marc.rhys-evans@terrapinn.com
+44 20 7827 5945

 

 

 

To Register

Tayyab Abbasi
tayyab.abbasi@terrapinn.com
+44 20 7092 1210

 

 

 

Press Relations

Karina Kusova
karina.kusova@terrapinn.com
+44 20 7092 1071